Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;37(1):4-5.
doi: 10.1038/s41433-022-02177-1. Epub 2022 Jul 14.

Biosimilar anti-VEGF-Yardsticks to ensure biosimilarity

Ashish Sharma  1 , Nikulaa Parachuri  2 , Nilesh Kumar  3 , Francesco Bandello  4 , Baruch D Kuppermann  5
Affiliations

Biosimilar anti-VEGF-Yardsticks to ensure biosimilarity

Ashish Sharma et al. Eye (Lond). 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: CLINICAL RESEARCH: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; CONSULTANT: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. NK: None. NP: None.

References

    1. FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) https://investors.biogen.com/news-releases/news-release-details/fda-appr.... Accessed 06 June 2022.
    1. Ranibizumab Biosimilar (Byooviz) Gains EU Marketing Authorization. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-.... Accessed 06 June 2022.
    1. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product https://www.fda.gov/regulatory-information/search-fda-guidance-documents... Accessed 06 June 2022.
    1. Multidisciplinary: biosimilar. https://www.ema.europa.eu/en/human-regulatory/research-development/scien.... Accessed 06 June 2022.
    1. Sharma A, Kuppermann BD. Biosimilars for retinal diseases: understanding the phase 3 clinical trial design. Ophthalmology. 2022;129:65–6. doi: 10.1016/j.ophtha.2021.09.008. - DOI - PubMed

Substances